Pyxis Oncology (NASDAQ:PYXS – Free Report) had its price target reduced by Wedbush from $8.00 to $7.00 in a research report sent to investors on Friday morning,Benzinga reports. Wedbush currently has an outperform rating on the stock.
Several other equities research analysts have also issued reports on the company. HC Wainwright lifted their price target on Pyxis Oncology from $7.00 to $8.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Weiss Ratings restated a “sell (e+)” rating on shares of Pyxis Oncology in a report on Friday, September 25th. Wells Fargo & Company raised their price objective on shares of Pyxis Oncology from $12.00 to $19.00 and gave the company an “overweight” rating in a research report on Wednesday, September 9th. Finally, Stifel Nicolaus set a $5.00 target price on shares of Pyxis Oncology in a research note on Thursday. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $8.71.
Check Out Our Latest Stock Report on Pyxis Oncology
Pyxis Oncology Stock Performance
Shares of NASDAQ PYXS traded up $0.05 during mid-day trading on Friday, reaching $1.66. The company had a trading volume of 557,636 shares, compared to its average volume of 874,187. Pyxis Oncology has a twelve month low of $1.03 and a twelve month high of $5.55. The stock has a market capitalization of $138.46 million, a PE ratio of -1.28 and a beta of 1.41. The stock’s 50 day moving average is $2.51 and its 200-day moving average is $2.16.
Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.03. On average, sell-side analysts anticipate that Pyxis Oncology will post -1.21 EPS for the current year.
Institutional Trading of Pyxis Oncology
Large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC raised its stake in shares of Pyxis Oncology by 22.0% in the 1st quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock valued at $1,297,000 after acquiring an additional 160,300 shares in the last quarter. Commonwealth Equity Services LLC boosted its position in Pyxis Oncology by 14.8% during the third quarter. Commonwealth Equity Services LLC now owns 48,750 shares of the company’s stock worth $114,000 after purchasing an additional 6,295 shares during the period. Finally, T3 Companies LLC bought a new stake in Pyxis Oncology during the third quarter worth approximately $61,000. Institutional investors own 39.07% of the company’s stock.
About Pyxis Oncology
Pyxis Oncology, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue.
Pyxis Oncology’s pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways.
Further Reading
- Five stocks we like better than Pyxis Oncology
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
